Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 5/20 | 0.39 |
| ▸ | PDE6C | P51160 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | CACNB4 | O00305 | 2/20 | 0.34 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.34 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.34 |
| ▸ | CACNG3 | O60359 | 2/20 | 0.34 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | CACNB3 | P54284 | 2/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2656086 | 0.87 | PDE5A (0.41) | PDE5APDE6CHPGDHSD17B10KDM4E | |
| SCHEMBL2656333 | 0.82 | PDE5A (0.44) | PDE5APDE6CHPGDKDM4EMEN1 | |
| SCHEMBL2661083 | 0.80 | TP53 (0.38) | PDE5AHSD17B10CA1CA2MAPK1 | |
| SCHEMBL2660939 | 0.76 | PDE5A (0.43) | PDE5APDE6CKMT2AACHE | |
| SCHEMBL4924170 | 0.75 | TP53 (0.42) | PDE5AHPGDKDM4EMEN1KMT2A | |
| SCHEMBL2655495 | 0.75 | GABRG2 (0.43) | PDE5APDE6C | |
| SCHEMBL4917169 | 0.74 | PDE5A (0.42) | PDE5APDE6CHPGDKDM4EMEN1 | |
| SCHEMBL2658370 | 0.74 | PDE5A (0.47) | PDE5APDE6CKDM4EMEN1KMT2A | |
| SCHEMBL4915495 | 0.74 | PDE5A (0.41) | PDE5APDE6CPDE4D | |
| SCHEMBL2660973 | 0.74 | GABRG2 (0.52) | PDE5APDE6CPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2176263-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | AstraZeneca AB (SE) | 2010-04-21 | — | — | EP | claimed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | claimed |
| WO-2008155572-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | claimed |
| EP-2176263-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | AstraZeneca AB (SE) | 2010-04-21 | — | — | EP | disclosed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008155572-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | COMT, BACE1, BDNF | PDE5A 742/4885PDE6C 2133/4885HPGD 2039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.